#China #Chengdu #Drug Discovery #HitGen #OpenDEL™

HitGen Unveils OpenDEL™ 5.0: Advancing DEL Technology for Drug Discovery

In the rapidly evolving world of pharmaceutical research, having access to advanced technologies is imperative for developing new medicines. HitGen Inc. has taken a significant step forward in accelerating drug discovery with the launch of its latest DNA-encoded library (DEL) technology, OpenDEL™ 5.0. This innovative platform features a staggering 4 billion diverse compounds designed to help researchers identify small molecule hits for difficult biological targets more efficiently.

Enhancements in OpenDEL™ 5.0

OpenDEL™ 5.0 marks a noteworthy upgrade from its predecessor, featuring several key enhancements:

1. Expanded Chemical Diversity: The new library comprises an impressive 3.8 billion small molecule compounds and 200 million peptide compounds. This expansion results in a 25% increase in library size, allowing researchers to explore a broader chemical landscape tailored for targeting protein-protein interactions (PPI).

2. Comprehensive Library Design: A total of 59 distinct libraries are available, providing a versatile range of chemistries suitable for various types of targets and discovery challenges. This diversity enables researchers to customize their approaches based on the unique demands of their projects.

3. Macrocycle Library: As an exciting new feature, OpenDEL™ 5.0 introduces an optional macrocycle library. This add-on comprises compounds containing 4-10 amino acids in a ring structure, accompanied by a linear peptide control library to assess the effectiveness of these macrocyclic compounds in designated applications.

4. Flexibility with Dual-Kit Options: Users can now choose between two offerings: OpenDEL™-Small Molecules or OpenDEL™-Macrocycle. Researchers have the option to combine both kits, significantly enhancing their discovery capabilities and coverage.

5. Streamlined Workflow: Redesigning protocols with intuitive visual guides simplifies critical steps, thus reducing onboarding time for new users. Along with expedited next-day shipping options, researchers can minimize the time between ordering and starting their explorations.

Availability and Global Reach

OpenDEL™ 5.0 is available worldwide, allowing scientists in both industry and academia to leverage its capabilities in their drug discovery efforts. The platform is designed to democratize access to cutting-edge DEL technology, catering to a wide range of research projects and challenges.

For scientists looking to advance their drug discovery initiatives or to explore the extensive chemical spaces offered by OpenDEL™ 5.0, the platform is easily accessible via HitGen's official website. By harnessing the unique advantages of DEL technology, researchers can significantly enhance their ability to discover new, effective treatments for various diseases.

Conclusion

The introduction of OpenDEL™ 5.0 by HitGen Inc. represents a remarkable advancement in drug discovery technologies, breaking barriers and providing invaluable tools for researchers. With its vast array of compounds, flexible usage options, and streamlined processes, OpenDEL™ 5.0 aims to propel the pharmaceutical industry toward discovering innovative therapies faster and more effectively than ever before. Monitor upcoming research breakthroughs powered by this leading-edge technology and witness how OpenDEL™ 5.0 reshapes the landscape of drug discovery.

For more information, reach out to the HitGen team or visit their website.